Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple
    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • DCC-2618-01-001 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20170452

    		SDG: Neurological Cancer
    Disease Site(s):

    Esophagus,Brain and Nervous System,Other Hematopoietic,Stomach,Small Intestine,Colon,Rectum,Other Digestive Organ
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    DCC-2618-01-001: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety,Tolerability, Efficacy, and Pharmacokinetics in Patients with AdvancedMalignancies
    Eligibility Criteria - NCT02571036 *This information has been extracted from " www.clinicaltrials.gov"

  • C-610-01 - Hosein, Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20180763

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Breast,Bladder,Rectum,Soft Tissue,Melanoma, skin
    Sponsor: Agenus

    Enrolling Sites:

    Sylvester
    Title:

    C-610-01:A Phase 1a First-in-Human Study of Safety and Tolerability of ASV? AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects with Solid Tumor at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection
    Eligibility Criteria - NCT03673020 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    		SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin
    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:

    IRB: 20191076

    		SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin
    Sponsor: EISAI

    Enrolling Sites:

    Sylvester
    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101
    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160023 - Kobetz Erin

  • Investigator:
    Erin Kobetz
    RCname Email

    		Coordinator:

    IRB: 20160023

    		SDG: Population Sciences
    Disease Site(s):

    Cervix Uteri,Other Hematopoietic,Colon,Rectum,Liver
    Sponsor: NIMHD

    Enrolling Sites:

    Community Clinics
    Sylvester
    Title:

    Increasing Uptake of Evidence Based Screening Services through a CHW led multi modality intervention: South Florida Center for Reducing Health Disparities.
    Eligibility Criteria - NCT02970136 *This information has been extracted from " www.clinicaltrials.gov"

  • TAB001-01 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    		Coordinator:

    IRB: 20190182

    		SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Other Endocrine System,Colon
    Sponsor: TABS

    Enrolling Sites:

    Sylvester
    Title:

    TAB001-01: tle ICMJEA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
    Eligibility Criteria - NCT03474640 *This information has been extracted from " www.clinicaltrials.gov"

  • BLU-667-1101 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170957

    		SDG: Thoracic Oncology
    Disease Site(s):

    Thyroid,Other Endocrine System,Colon,Lung
    Sponsor: Blueprint Medicines

    Enrolling Sites:

    Sylvester
    Title:

    BLU-667-1101: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
    Eligibility Criteria - NCT03037385 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue
    Sponsor: CP

    Enrolling Sites:

    Sylvester
    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Colon,Breast-Female,Melanoma, skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • TTX-030-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20181017

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Colon,Pancreas
    Sponsor: TTH

    Enrolling Sites:

    Sylvester
    Title:

    TTX-030-001 : Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy inPatients with Lymphoma or Solid Tumor Malignancies
    Eligibility Criteria - NCT03884556 *This information has been extracted from " www.clinicaltrials.gov"

  • EA2165 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20181112

    		SDG: Colorectal Cancer
    Disease Site(s):

    Anus
    Sponsor: ECOG

    Enrolling Sites:

    Gables
    Kendall
    Sylvester
    Title:

    EA2165:A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
    Eligibility Criteria - NCT03233711 *This information has been extracted from " www.clinicaltrials.gov"

  • HCRN GI16-288 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:

    IRB: 20181181

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon,Rectum
    Sponsor: Hoosier Oncology Group

    Enrolling Sites:

    Gables
    Kendall
    Sylvester
    Title:

    HCRN GI16-288: A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
    Eligibility Criteria - NCT03547999 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190732 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20190732

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon,Rectum
    Sponsor: ISOFOL MEDICAL AB

    Enrolling Sites:

    Sylvester
    Title:

    A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
    Eligibility Criteria - NCT03750786 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:
    RCemailImg Sarah Lam
    RCphone 3052437586

    IRB: 20160656

    		SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Other Hematopoietic,Anus,Lung
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • Anchor Study - Rosa-cunha, Isabella

  • Investigator:
    Isabella Rosa-cunha
    RCname Email

    		Coordinator:

    IRB: 20160316

    		SDG: Population Sciences
    Disease Site(s):

    Anus
    Sponsor: NIH

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    ANCHOR: Anal Cancer Prevention Study Anal Cancer HSIL Outcomes Research Study
    Eligibility Criteria - NCT02135419 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • LUD2015-008 - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    		Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170230

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary,Colon,Rectum
    Sponsor: LUDWIG INSTITUTE FOR CANCER RESEARCH

    Enrolling Sites:

    Sylvester
    Title:

    LUD2015-008: A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies
    Eligibility Criteria - NCT02963831 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180880 - Sussman Daniel

  • Investigator:
    Daniel Sussman
    RCname Email

    		Coordinator:

    IRB: 20180880

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon
    Sponsor: Janssen

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis
    Eligibility Criteria - NCT03649971 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190673 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190673

    		SDG: Breast Cancer
    Disease Site(s):

    Esophagus,Breast,Ovary,Other Female Genital,Kidney,Stomach,Colon,Lung
    Sponsor: MTEM

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"